Intermittent L-DOPA treatment differentially alters synaptotagmin 4 and 7 gene expression in the striatum of hemiparkinsonian rats

Brain Research
Gordana Glavan

Abstract

Long-term use of L-DOPA in Parkinson's disease (PD) is frequently associated with side effects that are reflected in changed neurotransmitter/neuropeptide secretion in basal ganglia. These side effects could be connected with synaptotagmins (syts) because syts are involved in regulation of membrane trafficking. We have previously reported that acute L-DOPA treatment upregulated the expression of Syt 4 and Syt 7 mRNAs in hypersensitive striatum of 6-OHDA rat model for PD. Here we investigate whether intermittent L-DOPA treatment that produces behavior sensitization affects the Syt 1, Syt 2, Syt 4, Syt 7 and Syt 10 mRNAs in striatum of 6-OHDA rats killed 4 and 12 h after the last L-DOPA injection. We verified behavioral sensitization by increased intensity of contralateral turning. 6-OHDA lesion caused Syt 2 mRNA downregulation and Syt 10 mRNA upregulation in striatum, but failed to alter Syt 4, Syt 7 and Syt 1 mRNAs. Acute l-DOPA induced an increase of Syt 4 and Syt 7 mRNAs in the denervated striatum leaving the levels of Syt 1, Syt 2 and Syt 10 mRNAs unaffected. Intermittent L-DOPA treatment did not alter Syt 1, Syt 2 and Syt 10 mRNA striatal levels, suggesting that 6-OHDA-induced Syt 2 and Syt 10 mRNA changes reflect a persist...Continue Reading

References

Oct 1, 1989·Trends in Neurosciences·R L AlbinJ B Penney
Mar 14, 1995·Proceedings of the National Academy of Sciences of the United States of America·L VicianH R Herschman
Mar 18, 1997·Proceedings of the National Academy of Sciences of the United States of America·J M BabityH A Robertson
Oct 31, 1998·Brain Research. Molecular Brain Research·T NakaharaH Uchimura
Mar 22, 2000·The Journal of Cell Biology·I MartinezN W Andrews
Jul 25, 2000·The Journal of Biological Chemistry·C von PoserR G Anderson
Jun 20, 2002·The Biochemical Journal·Mitsunori FukudaKatsuhiko Mikoshiba
Jun 14, 2003·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Steven U Walkley
Oct 9, 2003·The EMBO Journal·Tuhin VirmaniEge T Kavalali
Jan 7, 2004·The Pharmacogenomics Journal·S RappJ Thome
Oct 22, 2004·Journal of Biochemistry·Mitsunori Fukuda, Akitsugu Yamamoto
Apr 28, 2006·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Rosa M E Arantes, Norma W Andrews
Jun 23, 2006·Nature·Anthony HoltmaatKarel Svoboda
Jul 19, 2006·Cell and Tissue Research·Chiara SalioAdalberto Merighi
Sep 1, 2006·Journal of Neurochemistry·M Angela Cenci, Martin Lundblad
Nov 16, 2006·Annals of the New York Academy of Sciences·Jianhua Zhang, Ming Xu
Apr 3, 2007·Trends in Neurosciences·M Angela Cenci
Apr 20, 2007·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Katherine Leitzell
Aug 28, 2007·Neuroscience Letters·Robert PalGordana Glavan

❮ Previous
Next ❯

Citations

Jun 20, 2012·Basal Ganglia·Kathy Steece-CollierKatherine Soderstrom
Nov 28, 2009·The Anatomical Record : Advances in Integrative Anatomy and Evolutionary Biology·Gordana GlavanMarko Zivin
Aug 10, 2011·Journal of the Neurological Sciences·Nikoletta SzabóLaszló Vécsei

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal ganglia in Parkinson's disease (MDS)

The basal ganglia is comprised of the neostriatum, the external and internal pallidal segments, the subthalamic nucleus, the substantia nigra pars reticulata, and the pars compacta of the substantia nigra. The basal ganglia circuitry is responsible for the correct execution of voluntary movements and is implicated in Parkinson's disease. Here is the latest research investigating the basal ganglia in Parkinson's disease.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.